GLP-1 Receptor Agonists Show Modest Reductions in Alcohol Consumption and Craving in Systematic Review
Background
Alcohol use disorder (AUD) is a pervasive public health challenge, often co-occurring with metabolic dysfunction like type 2 diabetes mellitus and obesity. Current pharmacotherapies for AUD have limited efficacy or significant side effects, leaving a substantial treatment gap. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), primarily known for their metabolic benefits, have shown preclinical promise in modulating reward pathways and reducing addictive behaviors, including alcohol intake. This systematic review synthesizes clinical evidence to evaluate the potential role of GLP-1RAs in managing AUD.
Study Design
Researchers conducted a systematic review following PRISMA 2020 guidelines, searching PubMed and Web of Science from inception to December 2025. Eligible studies included randomized controlled trials (RCTs), secondary analyses of RCTs, and observational studies reporting quantitative alcohol consumption outcomes in adults with alcohol use or AUD. Data extraction and risk of bias assessment (using RoB 2 for RCTs and ROBINS-I for observational studies) were performed independently by two reviewers. The review ultimately included five studies, encompassing a total of n = 49,892 participants.
Results
The systematic review identified five studies (n = 49,892), comprising three RCT-based analyses and one large cohort study. Semaglutide and dulaglutide consistently demonstrated modest reductions in alcohol consumption and craving across several studies, with statistically significant improvements observed in selected behavioral outcomes. For instance, the cohort study reported small but statistically significant reductions in AUDIT-C scores following GLP-1RA initiation.
In contrast, exenatide did not show significant effects in the overall AUD population, with any signals limited to specific subgroups. Objective measures of alcohol use, such as
PEth(phosphatidylethanol) and breath alcohol concentration, also indicated reductions in selected contexts, though these were reported in only a few of the included studies. The evidence, while promising, was noted to be limited and heterogeneous.
Key Findings
- GLP-1RAs were associated with modest reductions in alcohol consumption and craving across five studies (n=49,892).
- Semaglutide and dulaglutide showed statistically significant improvements in selected alcohol-related behavioral outcomes.
- A large cohort study reported small but statistically significant reductions in
AUDIT-Cscores after GLP-1RA initiation. - Exenatide did not demonstrate significant effects in the overall AUD population.
- Objective measures like
PEthand breath alcohol concentration showed reductions in some contexts.
Why It Matters
This systematic review suggests GLP-1RAs may offer a novel adjunctive strategy for individuals struggling with alcohol use disorder, particularly those with co-occurring metabolic conditions. While the reductions in alcohol consumption were modest, the potential for a dual-benefit medication addressing both metabolic health and addiction is significant. For biohackers and clinicians, this highlights an emerging off-label application, prompting consideration of GLP-1RAs like semaglutide or dulaglutide in discussions with patients where AUD is a concern. However, the evidence base is still nascent; robust, dedicated RCTs are crucial to define optimal dosing, duration, and patient populations before widespread clinical translation or protocol recommendations can be made. This finding reinforces the pleiotropic effects of GLP-1RAs beyond glucose and weight management.
glp-1ra
alcohol-use-disorder
aud
systematic-review
semaglutide
dulaglutide